Primary ipilimumab/nivolumab immunotherapy followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome

被引：2
|
作者：
Cocorocchio, E. [1 ]
Nezi, L. [2 ]
Gandini, S. [2 ]
Manzo, T. [2 ]
Mazzarella, L. [2 ]
Lotti, F. [2 ]
Pala, L. [3 ]
Gnagnarella, P. [2 ]
Conforti, F. [3 ]
Pennacchioli, E. [4 ]
Fierro, M. T. [5 ]
Ribero, S. [6 ]
Senetta, R. [5 ]
Picciotto, F. [7 ]
Caliendo, V. [7 ]
Quaglino, P. [5 ]
Mazzarol, G. [3 ,8 ]
Orsolini, G. M. [4 ]
Prestianni, P. [4 ]
Ferrucci, P. F. [9 ]
机构：
[1] IRCCS, Ist Europeo Oncol, Hematoncol, Milan, Italy
[2] IRCCS, Ist Europeo Oncol, Experimental Oncol, Milan, Italy
[3] IRCCS, Ist Europeo Oncol, Med Oncol Melanoma Sarcoma & Rare Tumors, Milan, Italy
[4] IRCCS, Ist Europeo Oncol, Sarcoma & Rare Tumors, Surg Melanoma, Milan, Italy
[5] AOU Citta Salute & Sci Torino, Med Sci, Turin, Italy
[6] Azienda Osped Univ San Giovanni Battista Torino, Med Sci Dept, Turin, Italy
[7] AOU Citta Salute & Sci Torino Turin, Dermatol Surg, Turin, Italy
[8] IRCCS, Ist Europeo Oncol, Pathol & Lab Med, Milan, Italy
[9] IRCCS, Ist Europeo Oncol, Oncol Dept, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1457
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1072P
引用
收藏
页码：S889 / S890
页数：2
相关论文
共 50 条
  • [31] Induction Exposure Dose of Ipilimumab and Failure of Adjuvant Nivolumab Plus Ipilimumab in Melanoma
    Augustin, Ryan C.
    Luke, Jason J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 443 - +
  • [32] Bronchiolitis after Combination Immunotherapy With Ipilimumab and Nivolumab in a Melanoma Patient
    Basir, Shahir
    Bosiers, Jana
    Westgeest, Hans M.
    Yick, David C. Y.
    van Werven, Jochem R.
    van der Leest, Cor H.
    JOURNAL OF IMMUNOTHERAPY, 2024, 47 (07) : 263 - 265
  • [33] HEALTHCARE COST COMPARISON ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS NIVOLUMAB MONOTHERAPY AND IPILIMUMAB MONOTHERAPY IN ADVANCED MELANOMA
    Potluri, R.
    Bhandari, H.
    Ranjan, S.
    Moshyk, A.
    Kotapati, S.
    VALUE IN HEALTH, 2019, 22 : S72 - S73
  • [34] Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
    Potluri, Ravi
    Ranjan, Sandip
    Bhandari, Hitesh
    Johnson, Helen
    Moshyk, Andriy
    Kotapati, Srividya
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2019, 8 (1)
  • [35] Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
    Ravi Potluri
    Sandip Ranjan
    Hitesh Bhandari
    Helen Johnson
    Andriy Moshyk
    Srividya Kotapati
    Experimental Hematology & Oncology, 8
  • [36] An update on the safety of nivolumab for the treatment of advanced melanoma
    Czarnecka, Anna M.
    Rutkowski, Piotr
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (04) : 409 - 421
  • [37] Nivolumab and ipilimumab in combination with radiotherapy in patients with locally advanced head and neck cancer
    Johnson, J. M.
    Bar Ad, V.
    Lorber, E.
    Luginbuhl, A.
    Curry, J. M.
    Cognetti, D.
    Keith, S.
    Axelrod, R.
    Zinner, R.
    Rodeck, U.
    Harshyne, L. A.
    Argiris, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [38] Combination immunotherapy with ipilimumab and nivolumab in patients with advanced biliary tract cancers.
    Klein, Oliver
    Kee, Damien
    Nagrial, Adnan
    Ben Markman
    Underhill, Craig
    Michael, Michael
    Lum, Caroline
    Behren, Andreas
    Palmer, Jodie
    Tebbutt, Niall C.
    Carlino, Matteo S.
    Cebon, Jonathan S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] First-line nivolumab plus ipilimumab in advanced melanoma patients previously treated with adjuvant systemic therapy
    Kozak, K.
    Teterycz, P.
    Galus, L.
    Mackiewicz, J.
    Brandys, P.
    Cybulska-Stopa, B.
    Kempa-Kaminska, N.
    Zietek, M.
    Zubrowska, J.
    Dziura, R.
    Sobczuk, P.
    Czarnecka, A. M.
    Rutkowski, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S666 - S666
  • [40] COST EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF ADVANCED MELANOMA PATIENTS IN ENGLAND
    Lee, D.
    Amadi, A.
    Sabater, J.
    Ellis, J.
    Johnson, H.
    Roskell, N.
    Meng, Y.
    Patterson, K.
    VALUE IN HEALTH, 2016, 19 (07) : A731 - A731
12345